Sector ratings Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 10/12/2025 GMT			5-day change	1st Jan Change
1,991.50 ^DKK	-0.92%		-1.56%	+33.43%

12-09	BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours	MT
12-09	Genmab shares encouraging early-stage data on epcoritamab for RT patients	RE

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
GENMAB A/S	19.29B		AA
ARGENX SE	54.73B		AA
INSMED INCORPORATED	41.41B	-	BBB	-		-
WUXI APPTEC CO., LTD.	38.87B		AAA
BIONTECH SE	23.05B	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	17.8B		AAA
AKESO, INC.	14.13B		B			-
SUMMIT THERAPEUTICS INC.	13.12B	-	-	-		-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	12.78B	-	A	-		-
MADRIGAL PHARMACEUTICALS, INC.	12.58B	-	B	-		-
EXELIXIS, INC.	11.27B		BB
TRANSTHERA SCIENCES (NANJING), INC.	9.01B	-	-	-	-	-	-	-
ARROWHEAD PHARMACEUTICALS, INC.	9.35B	-	BBB	-		-
SAMSUNG EPIS HOLDINGS CO., LTD.	9.74B	-	-	-	-	-	-	-
NUVALENT, INC.	8.16B	-	CCC	-		-
CEREVEL THERAPEUTICS HOLDINGS, INC.	8.19B	-	-	-	-	-	-	-
CYTOKINETICS, INCORPORATED	7.53B	-	AA	-		-
METSERA, INC.	7.43B	-	B	-	-	-	-
MERUS N.V.	7.31B	-	BBB	-		-
ABL BIO INC.	6.99B	-	CCC	-		-
Average	16.64B		A
Weighted average by Cap.			A